Market Currents
Salix (SLXP -9.5%) shares slump on heavy trading after the FDA raises questions about the...
-
Monday, November 14, 2011, 3:40 PM ETSalix (SLXP -9.5%) shares slump on heavy trading after the FDA raises questions about the drugmaker's non-constipation irritable bowel syndrome treatment Xifaxan ahead of a Nov. 16 committee meeting. Some experts believe the unexpected questions could complicate approval, although others expect the drug ultimately will be approved.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
